Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
2.

SEL1L plays a major role in human malignant gliomas.

Mellai M, Annovazzi L, Boldorini R, Bertero L, Cassoni P, De Blasio P, Biunno I, Schiffer D.

J Pathol Clin Res. 2019 May 20. doi: 10.1002/cjp2.134. [Epub ahead of print]

3.

Glioblastoma: Microenvironment and Niche Concept.

Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M.

Cancers (Basel). 2018 Dec 20;11(1). pii: E5. doi: 10.3390/cancers11010005. Review.

4.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
5.

Correction: SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2018 Aug 24;9(66):32731. doi: 10.18632/oncotarget.26066. eCollection 2018 Aug 24.

6.

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.

Schiffer D, Mellai M, Boldorini R, Bisogno I, Grifoni S, Corona C, Bertero L, Cassoni P, Casalone C, Annovazzi L.

Int J Mol Sci. 2018 Sep 12;19(9). pii: E2724. doi: 10.3390/ijms19092724. Review.

7.

Glioblastoma niches: from the concept to the phenotypical reality.

Schiffer D, Mellai M, Bovio E, Bisogno I, Casalone C, Annovazzi L.

Neurol Sci. 2018 Jul;39(7):1161-1168. doi: 10.1007/s10072-018-3408-0. Epub 2018 May 8. Review.

PMID:
29736738
8.

Microglia immunophenotyping in gliomas.

Annovazzi L, Mellai M, Bovio E, Mazzetti S, Pollo B, Schiffer D.

Oncol Lett. 2018 Jan;15(1):998-1006. doi: 10.3892/ol.2017.7386. Epub 2017 Nov 9.

9.

Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.

Clemente N, Ferrara B, Gigliotti CL, Boggio E, Capucchio MT, Biasibetti E, Schiffer D, Mellai M, Annovazzi L, Cangemi L, Muntoni E, Miglio G, Dianzani U, Battaglia L, Dianzani C.

Int J Mol Sci. 2018 Jan 24;19(2). pii: E255. doi: 10.3390/ijms19020255.

10.

Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma.

Valentini MC, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, Casalone C, Maurella C, Grifoni S, Fania P, Cistaro A, Schiffer D.

Oncotarget. 2017 Oct 4;8(53):91636-91653. doi: 10.18632/oncotarget.21482. eCollection 2017 Oct 31.

11.

The neuropathological basis to the functional role of microglia/macrophages in gliomas.

Schiffer D, Mellai M, Bovio E, Annovazzi L.

Neurol Sci. 2017 Sep;38(9):1571-1577. doi: 10.1007/s10072-017-3002-x. Epub 2017 Jun 7. Review.

PMID:
28593528
12.

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Annovazzi L, Mellai M, Schiffer D.

Cancers (Basel). 2017 May 26;9(6). pii: E57. doi: 10.3390/cancers9060057. Review.

13.

Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.

Biasibetti E, Valazza A, Capucchio MT, Annovazzi L, Battaglia L, Chirio D, Gallarate M, Mellai M, Muntoni E, Peira E, Riganti C, Schiffer D, Panciani P, Lanotte M.

Comp Med. 2017 Mar 1;67(2):147-156.

14.

Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.

Battaglia L, Muntoni E, Chirio D, Peira E, Annovazzi L, Schiffer D, Mellai M, Riganti C, Salaroglio IC, Lanotte M, Panciani P, Capucchio MT, Valazza A, Biasibetti E, Gallarate M.

Nanomedicine (Lond). 2017 Mar;12(6):639-656. doi: 10.2217/nnm-2016-0380. Epub 2017 Feb 10.

PMID:
28186465
15.

A comprehensive view of tumor stem cells and their regulation by the microenvironment in glioblastoma.

Schiffer D, Annovazzi L, Mellai M.

Neurol Sci. 2017 Mar;38(3):527-529. doi: 10.1007/s10072-016-2768-6. Epub 2016 Nov 16. No abstract available.

PMID:
27853910
16.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
17.

Myeloperoxidase-responsive materials for infection detection based on immobilized aminomethoxyphenol.

Schiffer D, Tegl G, Vielnascher R, Weber H, Herrero-Rollett A, Sigl E, Heinzle A, Guebitz GM.

Biotechnol Bioeng. 2016 Dec;113(12):2553-2560. doi: 10.1002/bit.26025. Epub 2016 Jun 9.

PMID:
27241438
18.

Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach.

Senetta R, Mellai M, Manini C, Castellano I, Bertero L, Pittaro A, Schiffer D, Boldorini R, Cassoni P.

Histopathology. 2016 Aug;69(2):329-37. doi: 10.1111/his.12944. Epub 2016 Mar 21.

PMID:
26845757
19.

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma.

Denysenko T, Annovazzi L, Cassoni P, Melcarne A, Mellai M, Schiffer D.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):31-45.

20.

The Microenvironment in Gliomas: Phenotypic Expressions.

Schiffer D, Annovazzi L, Mazzucco M, Mellai M.

Cancers (Basel). 2015 Dec 3;7(4):2352-9. doi: 10.3390/cancers7040896.

21.

Fast Blue RR-Siloxane Derivatized Materials Indicate Wound Infection Due to a Deep Blue Color Development.

Schiffer D, Tegl G, Vielnascher R, Weber H, Schoeftner R, Wiesbauer H, Sigl E, Heinzle A, Guebitz GM.

Materials (Basel). 2015 Sep 25;8(10):6633-6639. doi: 10.3390/ma8105329.

22.

Neuroscience, the microscope and the truth: personal philosophical considerations by a professor emeritus of neuropathology and neurology.

Schiffer D.

Neurol Sci. 2016 Feb;37(2):323-7. doi: 10.1007/s10072-015-2335-6. Epub 2015 Jul 28.

PMID:
26216493
23.

Enzyme-responsive polymers for microbial infection detection.

Schiffer D, Tegl G, Heinzle A, Sigl E, Metcalf D, Bowler P, Burnet M, Guebitz GM.

Expert Rev Mol Diagn. 2015;15(9):1125-31. doi: 10.1586/14737159.2015.1061935. Epub 2015 Jul 16. Review.

PMID:
26184576
24.

Assessment of infection in chronic wounds based on the activities of elastase, lysozyme and myeloperoxidase.

Schiffer D, Blokhuis-Arkes M, van der Palen J, Sigl E, Heinzle A, Guebitz GM.

Br J Dermatol. 2015 Dec;173(6):1529-31. doi: 10.1111/bjd.13896. Epub 2015 Oct 29. No abstract available.

PMID:
25965963
25.

Biomarkers for infection: enzymes, microbes, and metabolites.

Tegl G, Schiffer D, Sigl E, Heinzle A, Guebitz GM.

Appl Microbiol Biotechnol. 2015 Jun;99(11):4595-614. doi: 10.1007/s00253-015-6637-7. Epub 2015 May 9. Review.

PMID:
25952112
26.

SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2015 May 20;6(14):12452-67. Erratum in: Oncotarget. 2018 Aug 24;9(66):32731.

27.

The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Annovazzi L, Caldera V, Mellai M, Riganti C, Battaglia L, Chirio D, Melcarne A, Schiffer D.

Int J Oncol. 2015;46(6):2299-308. doi: 10.3892/ijo.2015.2963. Epub 2015 Apr 16.

28.

Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?

Mellai M, Piazzi A, Casalone C, Grifoni S, Melcarne A, Annovazzi L, Cassoni P, Denysenko T, Valentini MC, Cistaro A, Schiffer D.

Onco Targets Ther. 2015 Feb 19;8:451-60. doi: 10.2147/OTT.S71384. eCollection 2015.

29.

Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment.

Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, Biasibetti E, Capucchio MT, Valazza A, Panciani P, Lanotte M, Annovazzi L, Caldera V, Mellai M, Filice G, Corona S, Schiffer D.

Eur J Pharm Biopharm. 2014 Nov;88(3):746-58.

30.

Stem cell niches in glioblastoma: a neuropathological view.

Schiffer D, Mellai M, Annovazzi L, Caldera V, Piazzi A, Denysenko T, Melcarne A.

Biomed Res Int. 2014;2014:725921. doi: 10.1155/2014/725921. Epub 2014 Apr 15.

31.

Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.

Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Biasibetti E, Capucchio MT, Valazza A, Panciani PP, Lanotte M, Schiffer D, Annovazzi L, Caldera V, Mellai M, Riganti C.

J Pharm Sci. 2014 Jul;103(7):2157-2165. doi: 10.1002/jps.24002. Epub 2014 May 13.

32.

Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones.

Schiffer D, Caldera V, Mellai M, Conforti P, Cattaneo E, Zuccato C.

Neuropathol Appl Neurobiol. 2014 Dec;40(7):899-910. doi: 10.1111/nan.12137.

PMID:
24634989
33.

Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.

Cattaneo M, Baronchelli S, Schiffer D, Mellai M, Caldera V, Saccani GJ, Dalpra L, Daga A, Orlandi R, DeBlasio P, Biunno I.

J Biol Chem. 2014 Jan 31;289(5):2826-38. doi: 10.1074/jbc.M113.527754. Epub 2013 Dec 5.

34.

Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.

Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.

Biomed Res Int. 2013;2013:756302. doi: 10.1155/2013/756302. Epub 2013 Sep 3.

35.

Sensor for early detection of wound infection.

Hajnsek M, Harrich D, Schiffer D, Guebitz G, Sinner F.

Biomed Tech (Berl). 2013 Aug;58 Suppl 1. pii: /j/bmte.2013.58.issue-s1-F/bmt-2013-4147/bmt-2013-4147.xml. doi: 10.1515/bmt-2013-4147. Epub 2013 Sep 7. No abstract available.

PMID:
24042782
36.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

37.

Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D.

Cell Mol Life Sci. 2014 Feb;71(3):499-516. doi: 10.1007/s00018-013-1397-y. Epub 2013 Jun 15.

38.

Novel protease-based diagnostic devices for detection of wound infection.

Heinzle A, Papen-Botterhuis NE, Schiffer D, Schneider KP, Binder B, Schintler M, Haaksman IK, Lenting HB, Gübitz GM, Sigl E.

Wound Repair Regen. 2013 May-Jun;21(3):482-9. doi: 10.1111/wrr.12040. Epub 2013 Apr 29.

PMID:
23627267
39.

Analysis of myeloperoxidase activity in wound fluids as a marker of infection.

Hasmann A, Wehrschuetz-Sigl E, Marold A, Wiesbauer H, Schoeftner R, Gewessler U, Kandelbauer A, Schiffer D, Schneider KP, Binder B, Schintler M, Guebitz GM.

Ann Clin Biochem. 2013 May;50(Pt 3):245-54. doi: 10.1258/acb.2011.010249.

PMID:
23404930
40.

MGMT hypermethylation and MDR system in glioblastoma cancer stem cells.

Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D.

Cancer Genomics Proteomics. 2012 Jul-Aug;9(4):171-8.

PMID:
22798502
41.

REST controls self-renewal and tumorigenic competence of human glioblastoma cells.

Conti L, Crisafulli L, Caldera V, Tortoreto M, Brilli E, Conforti P, Zunino F, Magrassi L, Schiffer D, Cattaneo E.

PLoS One. 2012;7(6):e38486. doi: 10.1371/journal.pone.0038486. Epub 2012 Jun 11. Erratum in: PLoS One. 2015;10(9):e0139645.

42.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
43.

Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres.

Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, Schiffer D.

J Oncol. 2011;2011:314962. doi: 10.1155/2011/314962. Epub 2011 Aug 18.

44.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
45.

SOX2 expression and amplification in gliomas and glioma cell lines.

Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D.

Cancer Genomics Proteomics. 2011 May-Jun;8(3):139-47.

PMID:
21518820
46.

PNET/ESFT of the cranial vault: a case report.

Mellai M, Caldera V, Comino A, Fortunato M, Bernucci C, Schiffer D.

Clin Neuropathol. 2010 Nov-Dec;29(6):372-7.

PMID:
21073841
47.

Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.

Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G.

Neuropathol Appl Neurobiol. 2011 Jun;37(4):381-94. doi: 10.1111/j.1365-2990.2010.01132.x.

PMID:
20946108
48.

On the origin and growth of gliomas.

Schiffer D, Annovazzi L, Caldera V, Mellai M.

Anticancer Res. 2010 Jun;30(6):1977-98. Review.

PMID:
20651342
49.

The history of neuropathology in Italy.

Schiffer D.

Clin Neuropathol. 2010 May-Jun;29(3):177-81.

50.

Neck pain during combat operations: an epidemiological study analyzing clinical and prognostic factors.

Cohen SP, Kapoor SG, Nguyen C, Anderson-Barnes VC, Brown C, Schiffer D, Turabi A, Plunkett A.

Spine (Phila Pa 1976). 2010 Apr 1;35(7):758-63. doi: 10.1097/BRS.0b013e3181bb11a8.

PMID:
20228712

Supplemental Content

Loading ...
Support Center